Marinus Pharmaceuticals Inc (FRA:61Y)
€ 0.302 0.002 (0.67%) Market Cap: 17.09 Mil Enterprise Value: 30.25 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 37/100

Q1 2023 Marinus Pharmaceuticals Inc Earnings Call Transcript

May 11, 2023 / 12:30PM GMT
Release Date Price: €8.6 (+1.78%)
Operator

Greetings, and welcome to the Marinus Pharmaceuticals First Quarter 2023 Financial Results and Business Update Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. And now it is my pleasure to introduce your host, Sasha Ellis, Senior Vice President of Corporate Affairs and Investor Relations. You may begin, Ms. Ellis.

Sasha Damouni Ellis
Marinus Pharmaceuticals, Inc. - SVP of Corporate Affairs & IR

Thank you, and good morning. With me from Marinus Pharmaceuticals are Dr. Scott Braunstein, Chairman and Chief Executive Officer; Christy Shafer, Chief Commercial Officer; Dr. Alex Aimetti, Chief Scientific Officer; and Steven Pfanstiel, Chief Financial Officer and Chief Operating Officer.

Before we begin, I would like to remind everyone that some of the statements we are making today are forward-looking statements under the securities laws. These forward-looking statements involve substantial risks and uncertainties that could cause our clinical development

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot